# US 2003/0215838 A1 · Cytokine receptor zcytor17 multimers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215838 A1
- Document ID: US20030215838A1
- Status: Published application
- Kind: A1
- Application number: 10/351,157
- Filed: 2003-01-21
- Published: 2003-11-20
- Earliest claimed: 2002-01-18
- Assignees: ZymoGenetics, Inc.
- Inventors: Cindy A. Sprecher; Zeren Gao; Joseph L. Kuijper; Maria M. Dasovich; Francis J. Grant; Scott R. Presnell; Theodore E. Whitmore; Angela K. Hammond; Julia E. Novak; Jane A. Gross; Stacey R. Dillon
- Web page: https://patentgrep.com/patent/US20030215838A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/715: for cytokines; for lymphokines; for interferons
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

## Claims

### Claim 1

An isolated multimeric or heterodimeric cytokine receptor comprising:
at least one polypeptide having at least 90 percent sequence identity with SEQ ID NO: 111 or SEQ ID NO: 109; and
wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising SEQ ID NO: 2.

### Claim 2 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 wherein the multimeric or heterodimeric cytokine receptor further comprises a cytokine-binding domain of a class I cytokine receptor.

### Claim 3 (depends on 2)

The isolated multimeric or heterodimeric cytokine receptor of claim 2 wherein the cytokine-binding domain of the class I cytokine receptor comprises amino acid residue 28 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 979 of SEQ ID NO: 7, or amino acid residue 1 to amino acid residue 979 of SEQ ID NO: 7.

### Claim 4 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 wherein the multimeric or heterodimeric cytokine receptor antagonizes an activity of SEQ ID NO: 2.

### Claim 5 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 wherein the multimeric or heterodimeric cytokine receptor inhibits proliferation of hematopoietic cells, inhibits proliferation of immune cells, inhibits proliferation of inflammatory cells, inhibits an immune response, inhibits an inflammatory response, or inhibits proliferation of tumor cells of epithelial origin.

### Claim 6 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 wherein the multimeric or heterodimeric cytokine receptor is soluble.

### Claim 7 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 further comprising an affinity tag or cytotoxic molecule.

### Claim 8 (depends on 7)

The isolated multimeric or heterodimeric cytokine receptor of claim 7 wherein the affinity tag is selected from the group of polyhistidine, protein A, glutathione S transferase, Glu-Glu, substance P, Flag™ peptide, streptavidin binding peptide, and immunoglobulin Fc polypeptide.

### Claim 9 (depends on 7)

The isolated multimeric or heterodimeric cytokine receptor of claim 7 wherein the cytotoxic molecule is a toxin or radionuclide.

### Claim 10 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 wherein the polypeptide having at least 90 percent identity with SEQ ID NO: 111 comprises amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 543 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 732 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 227, amino acid residue 1 to amino acid residue 519, amino acid residue 1 to amino acid residue 543, or amino acid residue 1 to amino acid residue 732.

### Claim 11 (depends on 1)

The isolated multimeric or heterodimeric cytokine receptor of claim 1 wherein the polypeptide having at least 90 percent identity with SEQ ID NO: 109 comprises amino acid residue 1 to amino acid residue 649 of SEQ ID NO: 109, or amino acid residue 20 to amino acid residue 649 of SEQ ID NO: 109.

### Claim 12

An isolated multimeric or heterodimeric cytokine receptor comprising at least one polypeptide comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111.

### Claim 13 (depends on 12)

The isolated multimeric or heterodimeric cytokine receptor of claim 12 wherein the polypeptide comprises amino acid residue 1 to amino acid residue 227 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 543 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 543 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 732 of SEQ ID NO: 111, or amino acid residue 20 to amino acid residue 732 of SEQ ID NO: 111.

### Claim 14 (depends on 12)

The isolated multimeric or heterodimeric cytokine receptor of claim 12 further comprising a cytokine-binding domain of a class I cytokine receptor.

### Claim 15 (depends on 14)

The isolated multimeric or heterodimeric cytokine receptor of claim 14 wherein the cytokine-binding domain of the class I cytokine receptor comprises amino acid residue 28 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 979 of SEQ ID NO: 7, or amino acid residue 1 to amino acid residue 979 of SEQ ID NO: 7.

### Claim 16 (depends on 12)

The isolated multimeric or heterodimeric cytokine receptor of claim 12 wherein the multimeric or heterodimeric cytokine receptor antagonizes an activity of a ligand comprising SEQ ID NO: 2.

### Claim 17 (depends on 12)

The isolated multimeric or heterodimeric cytokine receptor of claim 12 wherein the multimeric or heterodimeric cytokine receptor inhibits proliferation of hematopoietic cells, inhibits proliferation of immune cells, inhibits proliferation of inflammatory cells, inhibits an immune response, inhibits an inflammatory response, or inhibits proliferation of tumor cells of epithelial origin.

### Claim 18 (depends on 12)

The isolated multimeric or heterodimeric cytokine receptor of claim 12 wherein the multimeric or heterodimeric cytokine receptor is soluble.

### Claim 19 (depends on 12)

The isolated multimeric or heterodimeric cytokine receptor of claim 12 further comprising an affinity tag or cytotoxic molecule.

### Claim 20 (depends on 19)

The isolated multimeric or heterodimeric cytokine receptor of claim 19 wherein the affinity tag is selected from the group of polyhistidine, protein A, glutathione S transferase, Glu-Glu, substance P, Flag™ peptide, streptavidin binding peptide, and immunoglobulin Fc polypeptide.

### Claim 21 (depends on 19)

The isolated multimeric or heterodimeric cytokine receptor of claim 19 wherein the cytotoxic molecule is a toxin or radionuclide.

### Claim 22

An isolated polynucleotide that encodes a cytokine receptor polypeptide comprising an amino acid sequence having at least 90 percent sequence identity with SEQ ID NO: 111 or SEQ ID NO: 109, wherein the cytokine receptor polypeptide forms a multimeric or heterodimeric cytokine receptor, and wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising SEQ ID NO: 2.

### Claim 23 (depends on 22)

The isolated polynucleotide of claim 22 wherein the multimeric or heterodimeric cytokine receptor further comprises a cytokine-binding domain of a class I cytokine receptor.

### Claim 24

The isolated polynucleotide of claim of 23 wherein the cytokine-binding domain of the class I cytokine receptor comprises amino acid residue 28 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 979 of SEQ ID NO: 7, or amino acid residue 1 to amino acid residue 979 of SEQ ID NO: 7.

### Claim 25

The isolated polynucleotide of claim of 22 wherein the multimeric or heterodimeric cytokine receptor antagonizes an activity of SEQ ID NO: 2.

### Claim 26

The isolated polynucleotide of claim of 22 wherein the multimeric or heterodimeric cytokine receptor inhibits proliferation of hematopoietic cells, inhibits proliferation of immune cells, inhibits proliferation of inflammatory cells, inhibits an immune response, inhibits an inflammatory response, or inhibits proliferation of tumor cells of epithelial origin.

### Claim 27

The isolated polynucleotide of claim of 22 wherein the multimeric or heterodimeric cytokine receptor is soluble.

### Claim 28

The isolated polynucleotide of claim of 22 further comprising an affinity tag or cytotoxic molecule.

### Claim 29

The isolated polynucleotide of claim of 28 wherein the affinity tag is selected from the group of polyhistidine, protein A, glutathione S transferase, Glu-Glu, substance P, Flag™ peptide, streptavidin binding peptide, and immunoglobulin Fc polypeptide.

### Claim 30 (depends on 28)

The isolated polynucleotide of claim 28 wherein the cytotoxic molecule is a toxin or radionuclide.

### Claim 31 (depends on 22)

The isolated polynucleotide of claim 22 wherein the cytokine receptor polypeptide having at least 90 percent identity with SEQ ID NO: 111 comprises amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 543 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 732 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 227 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 543 of SEQ ID NO: 111, or amino acid residue 1 to amino acid residue 732 of SEQ ID NO: 111.

### Claim 32 (depends on 22)

The isolated polynucleotide of claim 22 wherein the cytokine receptor polypeptide having at least 90 percent identity with SEQ ID NO: 109 comprises amino acid residue 1 to amino acid residue 649 of SEQ ID NO: 109, or amino acid residue 20 to amino acid residue 649 of SEQ ID NO: 109.

### Claim 33

An isolated polynucleotide that encodes a cytokine receptor polypeptide comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111, wherein the cytokine receptor polypeptide forms a multimeric or heterodimeric cytokine receptor.

### Claim 34 (depends on 33)

The isolated polynucleotide of claim 33 wherein the cytokine receptor polypeptide comprises amino acid residue 1 to amino acid residue 227 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 519 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 543 of SEQ ID NO: 111, amino acid residue 20 to amino acid residue 543 of SEQ ID NO: 111, amino acid residue 1 to amino acid residue 732 of SEQ ID NO: 111, or amino acid residue 20 to amino acid residue 732 of SEQ ID NO: 111.

### Claim 35 (depends on 33)

The isolated polynucleotide of claim 33 wherein the multimeric or heterodimeric cytokine receptor further comprises a cytokine-binding domain of a class I cytokine receptor.

### Claim 36 (depends on 35)

The isolated polynucleotide of claim 35 wherein the cytokine-binding domain of the class I cytokine receptor comprises amino acid residue 28 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 429 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 739 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 1 to amino acid residue 761 of SEQ ID NO: 7, amino acid residue 28 to amino acid residue 979 of SEQ ID NO: 7, or amino acid residue 1 to amino acid residue 979 of SEQ ID NO: 7.

### Claim 37 (depends on 33)

The isolated polynucleotide of claim 33 wherein the multimeric or heterodimeric cytokine receptor antagonizes an activity of a ligand comprising SEQ ID NO: 2.

### Claim 38 (depends on 33)

The isolated polynucleotide of claim 33 wherein the multimeric or heterodimeric cytokine receptor inhibits proliferation of hematopoietic cells, inhibits proliferation of immune cells, inhibits proliferation of inflammatory cells, inhibits an immune response, inhibits an inflammatory response, or inhibits proliferation of tumor cells of epithelial origin.

### Claim 39 (depends on 33)

The isolated polynucleotide of claim 33 wherein the multimeric or heterodimeric cytokine receptor is soluble.

### Claim 40 (depends on 33)

The isolated polynucleotide of claim 33 wherein the multimeric or heterodimeric cytokine receptor further comprises an affinity tag or cytotoxic molecule.

### Claim 41 (depends on 40)

The isolated polynucleotide of claim 40 wherein the affinity tag is selected from the group of polyhistidine, protein A, glutathione S transferase, Glu-Glu, substance P, Flag™ peptide, streptavidin binding peptide, and immunoglobulin Fc polypeptide.

### Claim 42 (depends on 40)

The isolated polynucleotide of claim 40 wherein the cytotoxic molecule is a toxin or radionuclide.

### Claim 43

An expression vector comprising the following operably linked elements:
a transcription promoter;
a DNA segment encoding a cytokine receptor polypeptide having at least 90 percent sequence identity with SEQ ID NO: 111; and
a transcription terminator;
wherein the cytokine receptor polypeptide forms a multimeric or heterodimeric cytokine receptor, and wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising SEQ ID NO: 2.

### Claim 44

An expression vector comprising the following operably linked elements:
a) a first transcription promoter; a first DNA segment encoding a cytokine receptor polypeptide having at least 90 percent sequence identity with SEQ ID NO: 111; and a first transcription terminator; and
b) a second transcription promoter; a second DNA segment encoding a cytokine-binding domain of a class I cytokine receptor; and a second transcription terminator;
wherein the cytokine receptor polypeptide and the class I cytokine receptor form a multimeric or heterodimeric cytokine receptor; and
wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising SEQ ID NO: 2.

### Claim 45 (depends on 43)

A cultured cell comprising an expression vector of claim 43, wherein the cell expresses the cytokine receptor polypeptide encoded by the DNA segment.

### Claim 46 (depends on 44)

A cultured cell comprising an expression vector of claim 44, wherein the cell expresses the cytokine receptor polypeptide and the class I cytokine receptor encoded by the DNA segments.

### Claim 47

A cultured cell comprising:
a first expression vector comprising:
a) a transcription promoter;
b) a DNA segment encoding a cytokine receptor polypeptide having at least 90 percent sequence identity with SEQ ID NO: 111; and
c) a transcription terminator; and
a second expression vector comprising:
a) a transcription promoter;
b) a DNA segment encoding a cytokine-binding domain of a class I cytokine receptor; and
c) a transcription terminator;
wherein the cytokine receptor polypeptide and the class I cytokine receptor form a multimeric or heterodimeric cytokine receptor; and
wherein the multimeric or heterodimeric cytokine receptor binds to a ligand comprising SEQ ID NO: 2.

### Claim 48

A method of producing an antibody to a multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor, the method comprising:
inoculating an animal with the multimeric or heterodimeric cytokine receptor, wherein the multimeric or heterodimeric cytokine receptor elicits an immune response in the animal to produce an antibody that specifically binds the multimeric or heterodimeric cytokine receptor; and
isolating the antibody from the animal.

### Claim 49 (depends on 1)

An antibody that specifically binds to the multimeric or heterodimeric cytokine receptor of claim 1.

### Claim 50 (depends on 12)

An antibody that specifically binds to the multimeric or heterodimeric cytokine receptor of claim 12.

### Claim 51

A composition comprising:
an effective amount of a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor; and
a pharmaceutically acceptable vehicle.

### Claim 52 (depends on 45)

A method of producing a multimeric or heterodimeric cytokine receptor comprising:
culturing a cell according to claim 45; and
isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

### Claim 53 (depends on 46)

A method of producing a multimeric or heterodimeric cytokine receptor comprising:
culturing a cell according to claim 46; and
isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

### Claim 54 (depends on 47)

A method of producing a multimeric or heterodimeric cytokine receptor comprising:
culturing a cell according to claim 47; and
isolating the multimeric or heterodimeric cytokine receptor produced by the cell.

### Claim 55

An immune cell inhibiting composition comprising:
an effective amount of a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor; and
a pharmaceutically acceptable vehicle;
wherein the soluble multimeric or heterodimeric cytokine receptor inhibits proliferation of immune cells.

### Claim 56

An immune response inhibiting composition comprising:
an effective amount of a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor; and
a pharmaceutically acceptable vehicle;
wherein the soluble multimeric or heterodimeric cytokine receptor inhibits an immune response.

### Claim 57

An inflammatory cell inhibiting composition comprising:
an effective amount of a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor; and
a pharmaceutically acceptable vehicle;
wherein the soluble multimeric or heterodimeric cytokine receptor inhibits proliferation of inflammatory cells.

### Claim 58

An inflammatory response inhibiting composition comprising:
an effective amount of a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor; and
a pharmaceutically acceptable vehicle;
wherein the soluble multimeric or heterodimeric cytokine receptor inhibits an inflammatory response.

### Claim 59

A method of inhibiting an immune response in a mammal exposed to an antigen or pathogen, the method comprising:
(a) determining directly or indirectly the level of antigen or pathogen present in the mammal;
(b) administering a composition comprising a soluble multimeric or heterodimeric cytokine receptor in a pharmaceutically acceptable vehicle;
(c) determining directly or indirectly the level of antigen or pathogen in the mammal; and
(d) comparing the level of the antigen or pathogen in step (a) to the antigen or pathogen level in step (c), wherein a change in the level is indicative of inhibiting an immune response.

### Claim 60 (depends on 59)

The method of claim 59 further comprising:
(e) re-administering a composition comprising a multimeric or heterodimeric cytokine receptor in a pharmaceutically acceptable vehicle;
(f) determining directly or indirectly the level of antigen or pathogen in the mammal; and
(g) comparing the number of the antigen or pathogen level in step (a) to the antigen level in step (f), wherein a change in the level is indicative of inhibiting an immune response.

### Claim 61

A method for reducing hematopoietic cells and hematopoietic progenitor cells in a mammal, the method comprising:
culturing bone marrow or peripheral blood cells with a composition comprising an effective amount of a soluble multimeric or heterodimeric cytokine receptor to produce a decrease in the number of lymphoid cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of the multimeric or heterodimeric cytokine receptor.

### Claim 62 (depends on 61)

The method of claim 61 wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.

### Claim 63 (depends on 62)

The method of claim 62 wherein the lymphoid cells are monocytic cells, macrophages or T cells.

### Claim 64 (depends on 50)

A method of detecting the presence of a multimeric or heterodimeric cytokine receptor in a biological sample, comprising the steps of:
(a) contacting the biological sample with an antibody, or an antibody fragment, of claim 50, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample; and
(b) detecting any of the bound antibody or bound antibody fragment.

### Claim 65 (depends on 52)

A method of killing cancer cells comprising,
obtaining ex vivo a tissue or biological sample containing cancer cells from a patient, or identifying cancer cells in vivo;
producing a multimeric or heterodimeric cytokine receptor by the method of claim 52;
formulating the multimeric or heterodimeric cytokine receptor in a pharmaceutically acceptable vehicle; and
administering to the patient or exposing the cancer cells to the multimeric or heterodimeric cytokine receptor formulation;
wherein the multimeric or heterodimeric cytokine receptor kills the cells.

### Claim 66 (depends on 65)

A method of killing cancer cells of claim 65, wherein the multimeric or heterodimeric cytokine receptor is further conjugated to a toxin.

### Claim 67 (depends on 50)

The antibody of claim 50, wherein the antibody is from the group of: (a) polyclonal antibody, (b) murine monoclonal antibody, (c) humanized antibody derived from (b), (d) an antibody fragment, and (e) human monoclonal antibody.

### Claim 68

An antibody or antibody fragment that specifically binds to a multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor.

### Claim 69 (depends on 50)

The antibody of claim 50, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminscent marker, peptide tag, magnetic particle, drug, or toxin.

### Claim 70

A method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic progenitor cells comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of the soluble multimeric or heterodimeric cytokine receptor.

### Claim 71 (depends on 70)

The method of claim 70, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.

### Claim 72 (depends on 71)

The method of claim 71, wherein the lymphoid cells are macrophages or T cells.

### Claim 73

A method of reducing zcytor17lig-induced induced inflammation comprising administering to a mammal with inflammation an amount of a composition comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor sufficient to reduce inflammation.

### Claim 74

A method of suppressing an inflammatory response in a mammal with inflammation comprising:
(1) determining a level of an inflammatory molecule;
(2) administering a composition comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor in a pharmaceutically acceptable vehicle;
(3) determining a post administration level of the inflammatory molecule;
(4) comparing the level of the inflammatory molecule in step (1) to the level of the inflammatory molecule in step (3), wherein a lack of increase or a decrease the inflammatory molecule level is indicative of suppressing an inflammatory response.

### Claim 75 (depends on 68)

The antibody of claim 68, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

### Claim 76

A method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic progenitor cells comprising culturing bone marrow or peripheral blood cells with a composition comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor in a pharmaceutically acceptable vehicle sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble multimeric or heterodimeric cytokine receptor.

### Claim 77 (depends on 76)

The method of claim 76, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.

### Claim 78 (depends on 77)

The method of claim 77, wherein the lymphoid cells are macrophages or T cells.

### Claim 79

A method of reducing zcytor17lig-induced induced inflammation comprising administering to a mammal with inflammation an amount of a composition comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor in a pharmaceutically acceptable vehicle sufficient to reduce inflammation.

### Claim 80

A method of suppressing an inflammatory response in a mammal with inflammation comprising:
(1) determining a level of an inflammatory molecule;
(2) administering a composition comprising a multimeric or heterodimeric cytokine receptor which comprises amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 in a pharmaceutically acceptable vehicle;
(3) determining a post administration level of the inflammatory molecule;
(4) comparing the level of the inflammatory molecule in step (1) to the level of the inflammatory molecule in step (3), wherein a lack of increase or a decrease in the inflammatory molecule level is indicative of suppressing an inflammatory response.

### Claim 81

A method of treating a mammal afflicted with an inflammatory disease in which zcytor17lig plays a role, comprising:
administering an antagonist of zcytor17lig to the mammal such that the inflammation is reduced, wherein the antagonist is a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor in a pharmaceutically acceptable vehicle.

### Claim 82 (depends on 81)

A method of claim 81, wherein the disease is a chronic inflammatory disease.

### Claim 83 (depends on 82)

A method of claim 82, wherein the disease is a chronic inflammatory disease from the group of:
(a) inflammatory bowel disease;
(b) ulcerative colitis;
(c) Crohn's disease;
(d) atopic dermatitis;
(e) eczema; and
(f) psoriasis.

### Claim 84 (depends on 81)

A method of claim 81, wherein the disease is an acute inflammatory disease.

### Claim 85 (depends on 84)

A method of claim 84, wherein the disease is an acute inflammatory disease from the group of:
(a) endotoxemia;
(b) septicemia;
(c) toxic shock syndrome; and
(d) infectious disease.

### Claim 86 (depends on 81)

A method of claim 81, wherein the soluble multimeric or heterodimeric cytokine receptor further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

### Claim 87

A method for detecting inflammation in a patient, comprising:
obtaining a tissue or biological sample from a patient;
incubating the tissue or biological sample with a soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and a cytokine-binding domain of a class I cytokine receptor under conditions wherein the soluble multimeric or heterodimeric cytokine receptor binds to its complementary polypeptide in the tissue or biological sample;
visualizing the soluble multimeric or heterodimeric cytokine receptor bound in the tissue or biological sample; and
comparing levels of soluble multimeric or heterodimeric cytokine receptor bound in the tissue or biological sample from the patient to a normal control tissue or biological sample,
wherein an increase in the level of soluble multimeric or heterodimeric cytokine receptor bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of inflammation in the patient.

### Claim 88

A soluble multimeric or heterodimeric cytokine receptor comprising amino acid residue 20 to amino acid residue 227 of SEQ ID NO: 111 and amino acid residue 28 to amino acid residue 429 of SEQ ID NO: 7.
